FDA's Cardiovascular and Renal Drugs advisory committee voted 64 against approval of an NDA from Actavis plc NYSEACT for a fixeddose combination of nebivolol and valsartan to treat hypertension. The product has a Dec. 24 PDUFA date. In briefing documents r...
↧